Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Response begins trading on NASDAQ:

This article was originally published in Clinica

Executive Summary

Pharmacogenomic cancer diagnostics specialist Response Genetics commenced trading on the NASDAQ capital market last week (June 5) after issuing an initial public offering of 3 million shares of common stock priced at $7 per share. The Los Angeles, California-based firm intends to use the proceeds for research and development, business expansion and general corporate purposes. On first day of trading, its share price reached a high of $7.49 but closed at $7, the original opening price. The company is registered under the symbol "RGDX".

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel